EVANSTON, Ill., June 25, 2018 /PRNewswire/ -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders, today announced the closing of its initial public offering of 7,359,998 shares of common stock at a public offering price of $16.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 959,999 additional shares. The gross proceeds from the offering are expected to be $117.8 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares in the offering were offered by Aptinyx. The shares commenced trading on the NASDAQ Global Select Market on June 21, 2018 under the ticker symbol "APTX."
J.P. Morgan, Cowen, Leerink Partners, and BMO Capital Markets acted as book-running managers for the offering.
A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. Copies of the final prospectus relating to this offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions at 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Group or by telephone at (866) 803-9204; Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, by calling (631) 274-2806 or by faxing (631) 254-7140; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525, ext. 6132, or by email at firstname.lastname@example.org; or BMO Capital Markets Corp., 3 Times Square, 25th Floor, New York, NY 10036, Attention: Equity Syndicate Department, Telephone: (800) 414-3627, Email: email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx's lead programs focus on targeting and modulating N-methyl-D-aspartate receptors, NMDArs, which are vital to normal and effective function of the brain and nervous system.
View original content with multimedia:http://www.prnewswire.com/news-releases/aptinyx-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-300671912.html
SOURCE Aptinyx Inc.
Company Contact: Nick Smith, Director, Corporate Development, Aptinyx Inc., firstname.lastname@example.org, 847-871-0377; Media Contact: Jordann Phillips, Canale Communications, email@example.com, 619-849-6009